Biogen
Biogen is the 19th prescription drug company to announce conditions on 340B pricing when covered entities contract with outside pharmacies.

Breaking: Biogen Announces 340B Contract Pharmacy Restrictions

Biopharmaceutical manufacturer Biogen yesterday became the 19th prescription drug company to announce conditions on 340B pricing when covered entities contract with outside pharmacies.

Massachusetts-based Biogen posted a Dec. 12 letter to entities and an accompanying FAQ describing its new policy on drug industry contractor 340B ESP’s website. Its pricing limitation apply only Avonex and Plegridy, both of them injectable treatments for relapsing multiple sclerosis. Biogen reported $1.5 billion in revenue on the two medicines in 2021 on $10.9 billion in total global revenue.

Biopharmaceutical manufacturer Biogen yesterday became the 19th prescription drug company to announce conditions on 340B pricing when covered entities contract with outside pharmacies.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Attend Our Upcoming Webinar

×


Learn More

Sign up for our free news summaries and alerts